Abstract
In order to test the possible role of mGluR5 signaling in the behavioral endophenotypes of schizophrenia and other psychiatric disorders, we used genetic engineering to create mice carrying null mutations in this gene. Compared to their mGluR5+/+ littermates, mGluR5−/− mice have disrupted latent inhibition (LI) as measured in a thirst-motivated conditioned emotional response procedure. Administration of the positive modulator of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPAR), CX546, during the conditioning phase only, improved the disrupted LI in mGluR5 knockout mice and facilitated LI in control C57BL/6J mice, given extended number of conditioning trails (four conditioning stimulus–unconditioned stimulus). Prepulse inhibition (PPI) was impaired in mGluR5−/− mice to a level that could not be disrupted further by the antagonist of N-methyl-D-aspartate receptors—MK-801. PPI deficit of mGluR5−/− mice was effectively reversed by CX546, whereas aniracetam had a less pronounced effect. These data provide evidence that a potent positive AMPAR modulator can elicit antipsychotic action and represents a new approach for treatment of schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ango F, Prezeu L, Muller T, Tu JC, Xiao B, Worley PF et al (2001). Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411: 962–965.
Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20: 7871–7879.
Ballard TM, Puly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E et al (2002). Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22: 6713–6723.
Bardgett ME, Boeckman R, Krochmal D, Fernando H, Ahrens R, Csernansky JG (2003). NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57BL/6J mice. Brain Res Bull 60: 131–142.
Bills C, Schachtman TR, Serfozo P, Spooren WP, Gasparini F, Simonvi A (2005). Effects of metabotropic glutamate receptor 5 on latent inhibition in conditioned taste aversion. Behav Brain Res 157: 71–78.
Black MD (2005). Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berlin) 179: 154–163.
Braff D, Geyer MA, Swerdlow NR (2001). Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47: 181–188.
Brody SA, Conquet F, Geyer MA (2004b). Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172: 187–195.
Brody SA, Dulawa SC, Geyer MA, Conquet F (2004a). Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9: 35–41.
Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D et al (2000). Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39: 2223–2230.
Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapport JL, Hallet M (1996). Sensorimotor gaiting in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39: 33–41.
Chapman AG, Nanan K, Williams M, Meldrum BS (2000). Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39: 1567–1574.
Cohen E, Sereni N, Kaplan O, Weizman A, Kikinzon L, Weiner I et al (2004). The relation between latent inhibition and symptom—types in young schizophrenics. Behav Brain Res 149: 113–122.
Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Ann Rev pharmacol Toxicol 37: 261–281.
Depoortere R, Perrault G, Sanger DJ (1997). Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol 8: 364–372.
Devon RS, Anderson S, Teaguo PW, Muir WJ, Murray V, Pelosi AJ et al (2001). The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 6: 311–314.
Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE (1997). RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGluR5, but no mGluR1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36: 265–267.
Gainetdinov RR, Mohn AR, Bohn LM, Caron MG (2001). Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA 98: 11047–11054.
Gaisler-Salomon I, Weiner I (2003). Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berlin) 166: 333–342.
Geyer MA, Ellenbroek B (2003). Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071–1079.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berlin) 156: 117–154.
Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367–1377.
Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC et al (2001). A placebo-controlled pilot study of the AMPAkine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21: 484–487.
Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, Lucas LR et al (1999). The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 21: 434–439.
Goldman-Rakic PS (1994). Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6: 348–357.
Granger R, Staubli U, Davis M, Perez Y, Nilsson L, Rogers GA et al (1993). A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 15: 326–329.
Gray NS, Hemsley DR, Gray JA (1992). Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatr Brain Res 1: 83–89.
Hanley JG, Henley JM (2005). PICK1 is a calcium-sensor for NMDA-induced AMPA receptor trafficking. EMBO J 24: 3266–3278.
Hannan AJ, Blakemore C, Katsnelson A, Vitalis T, Huber KM, Bear M et al (2001). PLC-β1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat Neurosci 4: 282–288.
Henry SA, Dulawa SC, Conquet E, Geyer MA (1999). Sever disruption of prepulse inhibition (PPI) in mice lacking mGluR5. Soc Neurosci Abstr 25: 405–412.
Heuss C, Scanziani M, Gahwiler BH, Gerber U (1999). G-protein-independent signalling mediated by metabotropic glutamate receptors. Nat Neurosci 2: 1070–1077.
Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004). Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29: 1259–1269.
Huang Y, Lu W, Ali DW, Pelkey KA, Pitcher GM, Lu YM et al (2001). CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 29: 485–496.
Huang EP, Stevens CF (1998). The matter of mind: molecular control of memory. Essays Biochem 33: 165–178.
Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG (2000). Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 3: 661–669.
Isaac JTR, Nicoll RA, Malenka RC (1995). Evidence for silent synapses: implications for the expression of LTP. Neuron 15: 427–434.
Iwasato T, Erzurumlu RS, Huerta PT, Chen DF, Sasaoka T, Ulupinar E et al (1997). NMDA receptor-dependent refinement of somatotopic maps. Neuron 19: 1201–1210.
Javitt DC, Balla A, Sershen H, Lajtha A (1999). Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45: 668–679.
Javitt DC, Zukin SR (1991). Mechanisms of phencyclidine (PCP)-N-methyl-D-asparate (NMDA) receptor interaction: implications for schizophrenia. In: Tamminga CA, Schulz SC (eds). Neuropsychological Study of Schizophrenia in Schizophrenia Research: Advances in Neuropsychiatry and Psychopharmacology. Raven Press: New York. pp 13–20.
Jia Z, Lu Y, Henderson J, Taverna F, Romano C, Abramow-Newerly W et al (1998). Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 5: 331–343.
Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A et al (1999). Synergistic interactions between AMPAkines and antipsychotic drugs. J Pharmacol Exp Ther 289: 392–397.
Kew JNC, Kemp JA (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179: 4–29.
Kim JJ, Jung MW (2006). Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci Biobehav Rev 30: 188–202.
Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristol LJ et al (2003). Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306: 116–123.
Kozela E, Pilc A, Popik P (2003). Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-asparate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165: 245–251.
Larson J, Qach CN, LeDuc BQ, Nguyen A, Rogers GA, Lynch G (1996). Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res 738: 353–356.
LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155–184.
Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179: 54–67.
Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM et al (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17: 5196–5205.
Lynch G (2004). AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 4: 4–11.
Maren S, Tocco G, Standley S, Baudry M, Thompson RF (1993). Postsynaptic factors in the expression of long-term potentiation (LTP): increased glutamate receptor binding following LTP induction in vivo. Proc Natl Acad Sci USA 90: 9654–9658.
Morris RG, Davis S, Butcher SP (1990). Hippocampal synaptic plasticity and NMDA receptors: a role in information storage? Philos Trans R Soc Lond B Biol Sci 329: 187–204.
Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33: 275–307.
Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C (2001). Mechanisms and impact of allosteric AMPA receptor modulation by the AMPAkine CX546. Neuropharmacology 31: 650–663.
Ohnuma T, Augood SJ, Arai H, McKenna PJ, Ernson PC (1998). Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 56: 207–217.
Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatry Res 33: 523–533.
Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z et al (2001). The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology (Berlin) 156: 284–290.
Partin KM, Fleck MF, Mayer ML (1996). AMPA receptor flip/flop mutants affecting deactivation, desensitization and modulation by cyclothiazide, aniracetam and thiocyanate. J Neurosci 16: 6634–6647.
Paul IA, Skolnick P (2003). Glutamate and depression clinical and preclinical studies. Ann NY Acad Sci 1003: 250–272.
Salter MW, Kalia LV (2004). Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 5: 317–328.
Shadach E, Gaisler I, Schiller D, Weiner I. (2000). The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23: 151–161.
Smith AM, Wehner JM (2002). Aniracetam improves contextual fear conditioning and increases hippocampal γ-PKC activation in DBA/2J mice. Hippocampus 12: 76–85.
Spooren WP, Vassout A, Nejt HC, Kuhn R, Gasparini F, Roux S et al (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267–1275.
Staubli U, Rogers G, Lynch G (1994). Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91: 777–781.
Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gaiting in schizophrenia patients. Arch Gen Psychiatry 51: 139–154.
Swerdlow NR, Geyer MA (1993). Clozapine and haloperidol in an animal-model of sensoriomotor gaiting deficits in schizophrenia. Pharmacol Biochem Behav 44: 741–744.
Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swerdlow MR (1995). Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 58: 192–200.
Szumlinski KK, Lominac KD, Kleschen MJ, Oleson EB, Dehoff MH, Schwarz MK et al (2005). Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav 4: 273–278.
Tsuzuki K, Takeuchi T, Ozawa S (1992). Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam. Mol Brain Res 16: 105–110.
Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakemn P et al (1999). Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23: 583–592.
Ugolini A, Corsi M, Bordi F (1999). Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharm 38: 1569–1576.
Vanover KE (1997). Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur J Pharmacol 332: 115–119.
Wan FJ, Geyer MA, Swerdlow NR (1995). Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology (Berlin) 120: 433–441.
Weiner I (2003). The ‘two-headed’ latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berlin) 169: 257–297.
Weiner I, Lubow RE, Feldon J (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berlin) 83: 194–199.
Weiner I, Schiller D, Gaisler-Salomon I (2003). Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action. Neuropsychopharmacology 28: 499–509.
Weiner I, Shadach E, Barkai R, Feldon J (1997). Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanisms of action of neuroleptic drugs. Neuropsychopharmacology 16: 42–50.
Acknowledgements
We thank Alexander Kraev for genotyping, Ina Weiner for advice in setting up latent inhibition in mice. TL holds a CIHR Fellowship. This work was supported by the OMHF.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lipina, T., Weiss, K. & Roder, J. The Ampakine CX546 Restores the Prepulse Inhibition and Latent Inhibition Deficits in mGluR5-Deficient Mice. Neuropsychopharmacol 32, 745–756 (2007). https://doi.org/10.1038/sj.npp.1301191
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301191
Keywords
This article is cited by
-
Developmental up-regulation of NMDA receptors in the prefrontal cortex and hippocampus of mGlu5 receptor knock-out mice
Molecular Brain (2021)
-
Loss of retinoid X receptor gamma subunit impairs group 1 mGluR mediated electrophysiological responses and group 1 mGluR dependent behaviors
Scientific Reports (2021)
-
Anterior cingulate cortex dysfunction underlies social deficits in Shank3 mutant mice
Nature Neuroscience (2019)
-
Dendritic structural plasticity and neuropsychiatric disease
Nature Reviews Neuroscience (2018)
-
Iridium-catalyzed reductive Ugi-type reactions of tertiary amides
Nature Communications (2018)
